Bladder Cancer

>

Latest News

UGN-102 Shows Durable 1-Year Responses in Low-Grade, Intermediate-Risk NMIBC
UGN-102 Shows Durable 1-Year Responses in Low-Grade, Intermediate-Risk NMIBC

June 17th 2024

UGN-102 also demonstrated a 79.6% complete response rate at 3 months in the phase 3 ENVISION trial.

EV-302 PRO Outcomes Find Consistent Efficacy Data in Urothelial Carcinoma
EV-302 PRO Outcomes Find Consistent Efficacy Data in Urothelial Carcinoma

June 3rd 2024

Sacituzumab Govitecan Produces Finite Efficacy After Enfortumab Vedotin in Bladder Cancer Subsect
Sacituzumab Govitecan Produces Finite Efficacy After Enfortumab Vedotin in Bladder Cancer Subsect

June 3rd 2024

Sacituzumab Govitecan Yields Response But Questions Remain on Usefulness in Bladder Cancer
Sacituzumab Govitecan Yields Response But Questions Remain on Usefulness in Bladder Cancer

June 1st 2024

Avelumab Plus Chemo Improved Survival in Muscle-Invasive Urothelial Carcinoma
Avelumab Plus Chemo Improved Survival in Muscle-Invasive Urothelial Carcinoma

June 1st 2024

More News